pharma · Advanced Cancer · Non-small Cell Lung Cancer · RCUS
Arcus Biosciences
Arcus Biosciences is a pharma organization headquartered in Hayward, USA. It trades on NYSE under ticker RCUS. Primary therapeutic focus areas include Advanced Cancer, Non-small Cell Lung Cancer, Metastatic Clear Cell Re
Company details
- Status
- Public
- HQ
- 3928 Point Eden Way, Hayward, California 94545, US
- Founded
- 2015
- Employees
- 655
- Programs
- 53
- Drugs
- 25
- Patents
- 30
ARC-12
Phase 1 · other · Multiple Myeloma, Diffuse large B cell lymphoma (DLBCL), Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Melanoma, Advanced Solid Tumor, Gastrointestinal (GI) cancer, Hematological (heme) cancer, Gynecological (Gyn) cancer, Non-small cell lung cancer (NSCLC), Non-Hodgkin Lymphoma, Gastric Cancer, Cervical Cancer
ARC-12 for Multiple Myeloma, Diffuse large B cell lymphoma (DLBCL), Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Melanoma, Advanced Solid Tumor, Gastrointestinal (GI) cancer, Hematological (heme) cancer, Gynecological (Gyn) cancer, Non-small cell lung cancer (NSCLC), Non-Hodgkin Lymphoma, Gastric Cancer, Cervical Cancer is a Phase 1 program (other) at Arcus Biosciences with 1 ClinicalTrials.gov record(s).
Internal code ARC-12
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Arcus Biosciences
- Phase
- Phase 1
- Modality
- other
- Indication
- Multiple Myeloma, Diffuse large B cell lymphoma (DLBCL), Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Melanoma, Advanced Solid Tumor, Gastrointestinal (GI) cancer, Hematological (heme) cancer, Gynecological (Gyn) cancer, Non-small cell lung cancer (NSCLC), Non-Hodgkin Lymphoma, Gastric Cancer, Cervical Cancer
- Status
- active
- Trials
- 1